Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Genitourinary 1

Conditions

Lymphoma, Follicular 5Breast Neoplasms 5Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Lymphoma 4Waldenstrom Macroglobulinemia 3Recurrence 3Pancreatic Neoplasms 3Neoplasms 3Melanoma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3Burkitt Lymphoma 3Multiple Myeloma 2Lymphoma, Mantle-Cell 2Leukemia 2Glioma 2Glioblastoma 2Colorectal Neoplasms 2Brain Neoplasms 2Virus Diseases 1Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Select Advanced Solid Tumors 1Pregnancy Related 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Neuroectodermal Tumors 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Melanoma × Antibodies, Monoclonal × Clear all
NCT01335009 2021-09-01

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

Eisai Inc.

Phase 2 Completed
76 enrolled 13 charts
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00356460 2014-03-19

Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma

Sanofi

Phase 1 Completed
29 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT00094653 2011-07-11

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Bristol-Myers Squibb

Phase 3 Completed
1,783 enrolled 29 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡